With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Certain members of MotivHealth's HSA-based insurance plans will have access to DecisionRx's medication therapy optimization program.

Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...

The firm is gearing up for a registration-directed trial based on a positive Phase Ib readout and after discussions with US ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

Editas will receive $57 million in upfront cash from DRI Healthcare Trust in exchange for certain future licensing fees and ...

In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.

The decision reaffirming the FDA's oversight authority over cell and gene therapy products was praised by the International ...

Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which ...

The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.

In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.